Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 19c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $4.9 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Yum! Brands (YUM) PT Lowered to $180 at Argus